A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2005-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BMCL.2005.06.007PMID 15993593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The design, preparation and SAR of novel small molecule sodium (Na(+)) channel blockers.

  2004cited by this paper
• Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues.

  2003cited by this paper
• Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis.

  2003cited by this paper
• 3D QSAR in drug design.

  2002cited by this paper
• Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.

  2002cited by this paper
• Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4

  2000cited by this paper
• Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity.

  2000cited by this paper
• A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6.

  1999cited by this paper
• Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

  1994cited by this paper
• Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.

  1993cited by this paper
• Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes.

  1992cited by this paper
• Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

  1988cited by this paper

• Quantitative Structure-Activity Relationship (QSAR) Studies for the Inhibition of MAOs.

  2020cites this paper
• Computational prediction of cytochrome P450 inhibition and induction.

  2019cites this paper
• Improving the iterative Linear Interaction Energy approach using automated recognition of configurational transitions

  2016cites this paper
• In silico optimization of pharmacokinetic properties and receptor binding affinity simultaneously: a ‘parallel progression approach to drug design’ applied to β-blockers

  2016cites this paper
• Prediction of Metabolism of Drugs using Artificial Intelligence: How far have we reached?

  2016cites this paper
• Integrative Modeling Strategies for Predicting Drug Toxicities at the eTOX Project

  2015cites this paper
• Towards Automated Binding Affinity Prediction Using an Iterative Linear Interaction Energy Approach

  2014influential citation
• 2D QSAR of heteroaryl-substituted propanolamines as antihypertensive agents

  2014cites this paper
• Pharmacophore modeling for ADME.

  2013cites this paper
• Identification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysis.

  2012cites this paper
• Insights on Cytochrome P450 Enzymes and Inhibitors Obtained Through QSAR Studies

  2012influential citation
• Evaluation of pharmacological properties of Danshen compounds by computational and biochemical approaches

  2012cites this paper
• Optimizing QSAR Models for Predicting Ligand Binding to the Drug‐Metabolizing Cytochrome P450 Isoenzyme CYP2D6

  2011cites this paper
• Review of QSAR Models and Software Tools for predicting Biokinetic Properties

  2010cites this paper
• Understanding CYP2D6 interactions.

  2009cites this paper
• Structure of cytochrome p450s and personalized drug.

  2009cites this paper
• QSAR of cytochrome inhibitors

  2009cites this paper
• Classification of Cytochrome P450 Inhibitors with Respect to Binding Free Energy and pIC50 Using Common Molecular Descriptors

  2009cites this paper
• New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme

  2009influential citation
• Heme-iron complexing biphenyl and naphthalene derivatives as CYP17 inhibitorsfor the treatment of prostate cancer : design, synthesis and evaluation

  2009cites this paper
• QSAR Studies of CYP2D6 Inhibitor Aryloxypropanolamines Using 2D and 3D Descriptors

  2009influential citation
• Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.

  2008cites this paper
• Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450

  2008cites this paper
• Chapter 5 Linear Quantitative Structure–Activity Relationships for the Interaction of Small Molecules with Human Cytochrome P450 Isoenzymes

  2007cites this paper
• Pharmacophoric Fingerprint Method (TOPP) for 3D-QSAR Modeling: Application to CYP2D6 Metabolic Stability

  2007cites this paper
• Metabolism of N-substituted 7-methoxy-4-(aminomethyl) -coumarins by cytochrome P450 2D6 mutants and the indication of additional substrate interaction points

  2006cites this paper
• Recursive partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: importance of the quality of the dataset.

  2006cites this paper
• Computational models for predicting interactions with cytochrome p450 enzyme.

  2006cites this paper
• In-Silico ADME Modeling

  2006cites this paper